AP
PTX

Alydar Partners’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Alydar Partners’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-41,000
Closed -$3.85M – 113
2014
Q4 		$3.85M Buy
+41,000
New +$3.91M 0.61% 48

Other funds holding PTX

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

Alydar Partners's PTX Position: Q1 2015 in Review

Alydar Partners sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2015, closing a stake of 41,000 shares — an estimated $3.85M sold.

Alydar Partners first reported a position in PTX in Q4 2014 and held it in 1 quarter. The position peaked at $3.85M in Q4 2014. 117 funds tracked by Wall St. Rank hold PTX as of Q1 2015.

  • Alydar Partners reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2015 after selling out during the quarter.
  • Alydar Partners sold 41,000 Pernix Therapeutics Holdings, Inc. shares in Q1 2015, an estimated $3.85M.
  • Alydar Partners first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2014 and held it in 1 quarter.
  • Alydar Partners's Pernix Therapeutics Holdings, Inc. position peaked at $3.85M in Q4 2014.
  • 117 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2015.

Based on Alydar Partners's 13F filing for Q1 2015, filed 15 May 2015.